With the analysis paradigm of “structure-conduct-performance (SCP)” described in modern industrial organization theory, this paper analyzed the market structure, enterprise conduct and performance of biological pharmaceutical industry in China. It is suggested that the government to speed up the industrial restructuring, to optimize the industrial structure, to encourage the similar innovation, to optimize approval procedures of biological generics, etc.